Pure Biologics SA (PUR) Stock Statistics & Valuation Metrics

Pure Biologics SA has a market cap or net worth of zł26.45M. The enterprise value is zł30.84M.

Pure Biologics SA has 12,244,716 shares outstanding. The number of shares has decreased by -2.65% in one year.

Pure Biologics SA’s return on equity (ROE) is 0.69 and return on invested capital (ROIC) is -340.56%.

The current PE Ratio of Pure Biologics SA is ―. Pure Biologics SA’s PEG ratio is 0.04.

In the last 12 months, Pure Biologics SA had revenue of 0.00 and earned -9.82M in profits. Earnings per share was -1.99.

In the last 12 months, operating cash flow was -8.65M and capital expenditures 0.00, giving a free cash flow of -8.65M billion.

Pure Biologics SA pays an annual dividend of ―, resulting in a dividend yield of ―

Pure Biologics SA upcoming earnings date is ―, ―.

Pure Biologics SA as a current ratio of 0.25, with Debt / Equity ratio of -87.85%

In the past 12 months, Pure Biologics SA has paid 0.00 in taxes.

Pure Biologics SA EV to EBITDA ratio is -5.43, with an EV/FCF ratio of -5.34.

Pure Biologics SA has zł1.02M in cash and marketable securities with zł14.40M in debt, giving a net cash position of -zł13.38M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Pure Biologics SA is ―, which is 11.43% higher than the current price. The consensus rating is ―